1. Medtech Insight
  2. >>Policy & Regulation

Cardiac Monitoring Companies Fight Medicare Reimbursement Cut By Novitas

 
• By Reed Miller

Medicare carrier Novitas has proposed to cut reimbursement for long-term electrocardiogram monitoring, which could be a major headache for companies like iRhythm.

Scissors cut a $100 bill in half
• Source: shutterstock.com

Cardiac monitoring companies are trying to reverse a recent decision by Novitas Solutions, a regional Medicare carrier, to dramatically cut the 2021 reimbursement rates for long-term external electrocardiographic recording.

In recent years, companies that make wearable cardiac monitors have been lobbying the Centers for Medicare and Medicaid Services (CMS) to raise the national Medicare reimbursement rates for long-term cardiac monitoring with wearable devices, such as iRhythm Technologies’ Zio XT 14-day biosensor patch, Cardiac Insight’s Cardea SOLO

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

California Medtech Firms Resolve Patent Dispute Over Delivery Catheters

 
• By Brian Bossetta

Route 92 says it has reached a settlement with Q’Apel Medical over patent claims concerning its Tenzing delivery catheters.

Harbinger Health Targets High-Mortality Cancers First With AI-Driven MCED Platform

 
• By Shubham Singh

With a projected FDA submission within the next two to three years, Harbinger is prioritizing cancers based on lethality, prevalence, and unmet diagnostic need. Pancreatic and biliary cancers – often diagnosed at late stages and lacking established screening programs – will be among the initial targets.

Tariff Pressures Creep Into Dexcom’s Margin Outlook Despite Domestic Manufacturing Shield

 
• By Shubham Singh

Dexcom’s relatively strong position amid tariff-related uncertainty is rooted in its long-standing investments in domestic manufacturing, but raw material inflation is driving cost concerns even in the face of operational efficiencies.